These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 25761614)

  • 21. Peptidomimetic ethyl propenoate covalent inhibitors of the enterovirus 71 3C protease: a P2-P4 study.
    Ang MJ; Lau QY; Ng FM; Then SW; Poulsen A; Cheong YK; Ngoh ZX; Tan YW; Peng J; Keller TH; Hill J; Chu JJ; Chia CS
    J Enzyme Inhib Med Chem; 2016; 31(2):332-9. PubMed ID: 25792507
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A mechanistic view of enzyme inhibition and peptide hydrolysis in the active site of the SARS-CoV 3C-like peptidase.
    Yin J; Niu C; Cherney MM; Zhang J; Huitema C; Eltis LD; Vederas JC; James MN
    J Mol Biol; 2007 Aug; 371(4):1060-74. PubMed ID: 17599357
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure-guided design of potent and permeable inhibitors of MERS coronavirus 3CL protease that utilize a piperidine moiety as a novel design element.
    Galasiti Kankanamalage AC; Kim Y; Damalanka VC; Rathnayake AD; Fehr AR; Mehzabeen N; Battaile KP; Lovell S; Lushington GH; Perlman S; Chang KO; Groutas WC
    Eur J Med Chem; 2018 Apr; 150():334-346. PubMed ID: 29544147
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quaternary structure, substrate selectivity and inhibitor design for SARS 3C-like proteinase.
    Lai L; Han X; Chen H; Wei P; Huang C; Liu S; Fan K; Zhou L; Liu Z; Pei J; Liu Y
    Curr Pharm Des; 2006; 12(35):4555-64. PubMed ID: 17168761
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advanced simulations and screening to repurposing a 3C protease inhibitor against the rupintrivir-resistant human norovirus-induced gastroenteritis.
    Behmard E; Ghasemian A; Barzegari E; Farjadfar A; Kouhpayeh A; Najafipour S
    J Mol Graph Model; 2023 Jan; 118():108345. PubMed ID: 36308946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug design targeting the main protease, the Achilles' heel of coronaviruses.
    Yang H; Bartlam M; Rao Z
    Curr Pharm Des; 2006; 12(35):4573-90. PubMed ID: 17168763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease.
    Shie JJ; Fang JM; Kuo CJ; Kuo TH; Liang PH; Huang HJ; Yang WB; Lin CH; Chen JL; Wu YT; Wong CH
    J Med Chem; 2005 Jun; 48(13):4469-73. PubMed ID: 15974598
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ligand-induced Dimerization of Middle East Respiratory Syndrome (MERS) Coronavirus nsp5 Protease (3CLpro): IMPLICATIONS FOR nsp5 REGULATION AND THE DEVELOPMENT OF ANTIVIRALS.
    Tomar S; Johnston ML; St John SE; Osswald HL; Nyalapatla PR; Paul LN; Ghosh AK; Denison MR; Mesecar AD
    J Biol Chem; 2015 Aug; 290(32):19403-22. PubMed ID: 26055715
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus.
    Eleftheriou P; Amanatidou D; Petrou A; Geronikaki A
    Molecules; 2020 May; 25(11):. PubMed ID: 32485894
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, synthesis, and evaluation of trifluoromethyl ketones as inhibitors of SARS-CoV 3CL protease.
    Shao YM; Yang WB; Kuo TH; Tsai KC; Lin CH; Yang AS; Liang PH; Wong CH
    Bioorg Med Chem; 2008 Apr; 16(8):4652-60. PubMed ID: 18329272
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structural basis of mercury- and zinc-conjugated complexes as SARS-CoV 3C-like protease inhibitors.
    Lee CC; Kuo CJ; Hsu MF; Liang PH; Fang JM; Shie JJ; Wang AH
    FEBS Lett; 2007 Nov; 581(28):5454-8. PubMed ID: 17981158
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.
    Rathnayake AD; Zheng J; Kim Y; Perera KD; Mackin S; Meyerholz DK; Kashipathy MM; Battaile KP; Lovell S; Perlman S; Groutas WC; Chang KO
    Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32747425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a Gaussia luciferase-based human norovirus protease reporter system: cell type-specific profile of Norwalk virus protease precursors and evaluation of inhibitors.
    Qu L; Vongpunsawad S; Atmar RL; Prasad BV; Estes MK
    J Virol; 2014 Sep; 88(18):10312-26. PubMed ID: 25008934
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor.
    Yang S; Chen SJ; Hsu MF; Wu JD; Tseng CT; Liu YF; Chen HC; Kuo CW; Wu CS; Chang LW; Chen WC; Liao SY; Chang TY; Hung HH; Shr HL; Liu CY; Huang YA; Chang LY; Hsu JC; Peters CJ; Wang AH; Hsu MC
    J Med Chem; 2006 Aug; 49(16):4971-80. PubMed ID: 16884309
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure-based design and synthesis of macrocyclic human rhinovirus 3C protease inhibitors.
    Namoto K; Sirockin F; Sellner H; Wiesmann C; Villard F; Moreau RJ; Valeur E; Paulding SC; Schleeger S; Schipp K; Loup J; Andrews L; Swale R; Robinson M; Farady CJ
    Bioorg Med Chem Lett; 2018 Mar; 28(5):906-909. PubMed ID: 29433930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. α-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment.
    Zhang L; Lin D; Kusov Y; Nian Y; Ma Q; Wang J; von Brunn A; Leyssen P; Lanko K; Neyts J; de Wilde A; Snijder EJ; Liu H; Hilgenfeld R
    J Med Chem; 2020 May; 63(9):4562-4578. PubMed ID: 32045235
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 3C protease of enterovirus 68: structure-based design of Michael acceptor inhibitors and their broad-spectrum antiviral effects against picornaviruses.
    Tan J; George S; Kusov Y; Perbandt M; Anemüller S; Mesters JR; Norder H; Coutard B; Lacroix C; Leyssen P; Neyts J; Hilgenfeld R
    J Virol; 2013 Apr; 87(8):4339-51. PubMed ID: 23388726
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization and inhibition of norovirus proteases of genogroups I and II using a fluorescence resonance energy transfer assay.
    Chang KO; Takahashi D; Prakash O; Kim Y
    Virology; 2012 Feb; 423(2):125-33. PubMed ID: 22200497
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure-Guided Design of Potent Spirocyclic Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 3C-like Protease.
    Dampalla CS; Rathnayake AD; Galasiti Kankanamalage AC; Kim Y; Perera KD; Nguyen HN; Miller MJ; Madden TK; Picard HR; Thurman HA; Kashipathy MM; Liu L; Battaile KP; Lovell S; Chang KO; Groutas WC
    J Med Chem; 2022 Jun; 65(11):7818-7832. PubMed ID: 35638577
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The enterovirus protease inhibitor rupintrivir exerts cross-genotypic anti-norovirus activity and clears cells from the norovirus replicon.
    Rocha-Pereira J; Nascimento MS; Ma Q; Hilgenfeld R; Neyts J; Jochmans D
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4675-81. PubMed ID: 24890597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.